Tonix Pharmaceuticals Holding Corp.
Report topline data from the Phase 3 RALLY study
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company failed to report topline data by the Q4 2021 deadline, instead reporting it in March 2022.
-
A Tonix Pharmaceuticals Holding Corp. 10-K filed 2023-03-13
“We reported topline data from the completed study in March of 2022.” ✓ confirmed on the page
Market reaction: the shares moved -10.5% against the S&P 500 over the three sessions around the disclosure (10 Mar 2023 to 15 Mar 2023). What this measures
Checked 25 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 3 versions
-
Version 1 · original · stated 5 Jan 2021
Deadline 31 Dec 2021 (“in the fourth quarter of 2021”) · wording expected
-
Version 2 · stated 12 Jan 2021
Deadline 30 Jun 2021 (“in the second quarter of 2021”) · wording expected
“The Company expects interim data for the Phase 3 RALLY study in the second quarter of 2021”
-
Version 3 · stated 12 Jan 2021
Deadline 31 Dec 2021 (“in the fourth quarter of 2021”)
“topline data in the Phase 3 RALLY study in the fourth quarter of 2021.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 RALLY study topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Tonix Pharmaceuticals Holding Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TNXP-021077 · Corrections policy